Healthpeak reports third-quarter results and raises 2026 FFO guidance

Healthpeak reported third-quarter 2026 net income of $0.02 per diluted share and adjusted FFO of $0.44 per share, compared with a $0.17 loss and $0.46 of adjusted FFO in the prior-year quarter. The company raised its 2026 adjusted FFO guidance to $1.76–$1.78 per share and same-store cash NOI growth guidance to 0.5%–2.0%, while lowering earnings guidance to $0.39–$0.41 per share primarily because of depreciation from senior housing acquisitions. Healthpeak also acquired or agreed to acquire about $233 million of life science properties, entered a $500 million undrawn term loan facility, and reported 4.7x net debt to adjusted EBITDAre as of September 30, 2026.